

1 **Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in**
2 **type II and type III spinal muscular atrophy patients**

3 Iddo Magen^{1,2§}, Sharon Aharoni^{3,4§}, Nancy Sarah Yacovzada^{1,2}, Itay Tokatly Latzer^{4,5}, Christiano R R
4 Alves⁶, Liora Sagi^{4,5}, Aviva Fattal-Valevski^{4,5}, Kathryn J Swoboda⁶, Jacob Katz^{4,7}, Elchanan
5 Bruckheimer^{4,8}, Yoram Nevo^{3,4*} and Eran Hornstein^{1,2*}

6 ¹ Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

7 ² Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel

8 ³ Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

9 ⁴ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

10 ⁵ Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv,
11 Israel.

12 ⁶ Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital, Boston,
13 MA, USA.

14 ⁷ Division of Department of Anesthesia, Schneider Children's Medical Center of Israel, Petach Tikva,
15 Israel

16 ⁸ Cardiology Institute, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

17

18

19 § Equal contribution

20 * To whom correspondence should be addressed:

21 yoramne@clalit.org.il or eran.hornstein@weizmann.ac.il

22 **Abstract**

23 **Objective:** The antisense oligonucleotide nusinersen (spinraza) regulates splicing of the *survival motor*
24 *neuron 2 (SMN2)* messenger RNA to increase survival motor neuron (SMN) protein expression and
25 has improved ventilator free survival and motor function outcomes in infantile onset forms of SMA,
26 treated early in the course of the disease. However, the response in later onset forms of SMA is highly
27 variable and dependent on symptom severity and disease duration at treatment initiation. Therefore, we
28 aimed to identify novel noninvasive biomarkers that could predict the response to nusinersen in type II
29 and III SMA patients.

30 **Methods:** This is a multi-center longitudinal cohort study including a total of 34 type II or III SMA
31 patients. We applied unbiased next-generation sequencing to identify cell-free microRNAs in the
32 cerebrospinal fluid (CSF) as candidate biomarkers to predict response to nusinersen. Motor function,
33 assessed by the Hammersmith Functional Motor Scale Expanded (HFMSE), was considered the
34 primary clinical outcome. HFMSE was conducted at baseline and 6 months post initiation of
35 nusinersen therapy. Patients with an improvement ≥ 3 points or no change or decline < 0 points in the
36 HFMSE total score were considered to be responders or non-responders, respectively.

37 **Results:** Lower baseline levels of two muscle microRNAs (miR-206 and miR-133), alone or in
38 combination, were associated with the pre-determined clinical response to nusinersen after 6 months
39 therapy. Moreover, miR-206 levels were inversely correlated with the HFMSE score.

40 **Conclusions:** Lower miR-206 and miR-133 in the CSF predict more robust clinical response to
41 nusinersen treatment in later onset SMA patients. These novel findings have high clinical relevance for
42 identifying early treatment response to nusinersen in later onset SMA patients and call to test the
43 ability of miRNAs to predict more sustained long-term benefit.

44

45 **Introduction**

46 Spinal muscular atrophy (SMA) is a genetic pediatric disease with an incidence of ~ 1/11,000 live
47 births, and a carrier frequency of ~1/40^{1, 2}. SMA is characterized by muscle weakness and atrophy,
48 resulting from progressive degeneration of lower motor neurons in the spinal cord and the brain stem
49 nuclei. Historically, SMA subtype classification is based on age of onset and the maximum motor
50 abilities achieved. SMA type I patients have onset in early infancy and never sit. SMA type II patients
51 have later infantile onset but never walk. SMA type III patients have more variable childhood onset,
52 and achieve the ability to walk³. The cause of SMA are homozygous deletion or compound
53 heterozygous mutation involving exon 7 of the Survival Motor Neuron 1 (*SMN1*) gene. However,
54 *SMN1* has a paralogous gene named *SMN2*, which undergoes alternative splicing, including the
55 removal of exon 7, and produces ~10% functional SMN protein^{4, 5}. Therefore, the number of *SMN2*
56 copies correlates with phenotypic severity and is the main genetic disease modifier⁶⁻⁸.

57 Nusinersen was the first drug approved by the US Food and Drug Administration (FDA) to precisely
58 treat SMA. The drug is a synthetic antisense oligonucleotide that modulates pre-messenger RNA
59 splicing of the *SMN2* gene. Despite the advance of novel molecular and gene therapies for SMA,
60 nusinersen remains to this day the most widely used and available SMA disease-modifying therapy.
61 Nusinersen has been proven efficient in young type I SMA patients, and it is dramatically changing the
62 natural history of this disease^{9, 10}. However, the degree of response in subjects with later-onset forms of
63 SMA (type II and III) is highly dependent on age of treatment, time from symptom onset and severity
64 of denervation. Therefore, better understanding of the variable treatment response in this population is
65 important and novel biomarkers to predict treatment response to nusinersen in type II or type III SMA
66 subjects are critical.

67 A main interest of our group has been to investigate the profile of microRNAs (miRNAs) in the
68 disease context, since several endogenous non-coding RNAs are highly expressed in both neuronal and
69 muscular tissues. Previous evidence indicates that some miRNAs are essential for motor neuron
70 survival, and low expression levels have been demonstrated in motor neurons from an SMA mouse
71 model and in postmortem neuronal tissues from patients with another motor neuron disease,
72 amyotrophic lateral sclerosis (ALS)¹¹⁻¹³. Moreover, miRNAs known as myomiRs, such as miR-
73 1/133a/133b/206, are mainly expressed in the skeletal muscle, where they are thought to play an
74 important role in myoblast proliferation and differentiation^{14, 15}. Recent studies have demonstrated that
75 the expression of myomiRs can be detected and differentially expressed in biofluids from ALS patients

76 when compared to healthy controls¹⁶⁻¹⁸, suggesting a potential role of these molecules in the early
77 diagnosis of the disease. In addition, serum myomiRs are in correlation with the response to ongoing
78 therapy in SMA type II and III¹⁹. However, a prospective study that identifies responders to
79 Nusinersen therapy, based on a basal, pre-treatment, molecular profile, was not yet reported.

80 On the basis of understanding the miRNA role in motor neuron diseases¹¹⁻¹³ and potential discovery of
81 novel biomarkers²⁰⁻²², we sought to test the utility of specific miRNAs in the cerebrospinal fluid (CSF)
82 as candidate molecules to predict a positive clinical response to nusinersen in type II/III SMA patients.
83 We applied for the first time an unbiased next-generation sequencing to investigate the potential of
84 cell-free microRNAs in the CSF of SMA patients receiving nusinersen therapy. Our novel findings
85 indicate that the muscle miRNAs miR-206 and miR-133 are associated with the response to nusinersen
86 treatment and, therefore, have the potential to help predict, when combined with other indicators,
87 whether or not a given SMA patient is more or less likely to show an early response.

88

89 **Materials and Methods**

90 **Subjects, Ethics and Motor Function.** This study includes a cohort of 45 type II or type III SMA
91 patients, that were recruited between November 2016 and July 2019 in three different medical centers:
92 Schneider Children's Medical Center of Israel (Israel, n=13), Dana-Dwek Children's Hospital, Tel Aviv
93 Medical Center (Israel, n=20) and Massachusetts General Hospital (MA, US, n=12). Approval for the
94 study was provided by local ethical committees (Schneider Medical Center: RMC-0060-18; Tel Aviv
95 Medical Center: 0347-18-TLV; Massachusetts General Hospital MGH #2016P000469), and it was
96 conducted in accordance with the International Conference on Harmonization guidelines for Good
97 Clinical Practice and the World Medical Association Declaration of Helsinki. Written informed
98 parental consent were obtained from all participants. Nusinersen was administered on days 1, 15, 29,
99 and 64 for the loading phase, followed by an additional maintenance dose after 4 additional months
100 from the loading phase. Baseline demographic and clinical data were collected. Motor function was
101 assessed at each visit by a physical therapist with SMA clinical trial training²³ using Hammersmith
102 Functional Motor Scale Expanded (HFMSSE)²⁴. CSF samples were collected on day 1 and 183 right
103 before the nusinersen injection in each day and were stored frozen at -80°C.

104 **Inclusion and exclusion criteria.** All 45 patients had a genetic diagnosis for SMA, and were followed
105 up to this point. They were included in the study after verifying that for both day 1 and day 183, they
106 had non-hemolyzed CSF samples and record of their HFMSSE score.

107 An improvement at the HFMSE final score ≥ 3 points was considered clinically significant^{25, 26} and
108 patients with such an improvement were considered as ‘responders’, while those with a change of
109 HFMSE final score ≤ 0 were considered as ‘non-responders’. Samples from 11 patients with an
110 indefinite clinical response to nusinersen (HFMSE improvement of 1 or 2 points) were processed, but
111 were later excluded from further analysis, arriving a final study size of 34 patients. Based on power
112 analysis calculations, we found that this number was sufficient to obtain an effect size of 3 for change
113 in miRNA level with a power of 95% and a p-value of 0.01.

114

115 **Small RNA Next Generation Sequencing.** Total RNA was extracted from CSF using the miRNeasy
116 micro kit (Qiagen, Hilden, Germany) and quantified with Qubit fluorometer using RNA broad range
117 (BR) assay kit (Thermo Fisher Scientific, Waltham, MA). For small RNA next generation sequencing
118 (RNA-seq), libraries were prepared from 7.5 ng of total RNA using the QIAseq miRNA Library Kit
119 and QIAseq miRNA NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of
120 samples. Samples were randomly allocated to library preparation and sequencing in batches. Precise
121 linear quantification of miRNA is achieved by using unique molecular identifiers (UMIs), of random
122 12-nucleotide after 3’ and 5’ adapter ligation, within the reverse transcription primers²⁰. cDNA
123 libraries were amplified by PCR for 22 cycles, with a 3’ primer that includes a 6-nucleotide unique
124 index, followed by on-bead size selection and cleaning. Library concentration was determined with
125 Qubit fluorometer (dsDNA high sensitivity assay kit; Thermo Fisher Scientific, Waltham, MA) and
126 library size with TapeStation D1000 (Agilent). Libraries with different indices were multiplexed and
127 sequenced on NextSeq 500/550 v2 flow cell or Novaseq SP100 (Illumina), with 75bp single read and
128 6bp index read. Fastq files were de-multiplexed using the user-friendly transcriptome analysis pipeline
129 (UTAP)²⁷. Human miRNAs, as defined by miRBase²⁸, were mapped using Geneglobe Data Analysis
130 Center (Qiagen).

131 **Statistical analysis.** As many as 2530 individual miRNA species were aligned to the human genome
132 (GRCh37/hg19) across all samples. miRNAs with ≤ 100 UMIs on average across all samples were
133 excluded from analysis. Sequencing data were normalized with DESeq2 package²⁹ under the
134 assumption that miRNA counts followed negative binomial distribution and data were corrected for the
135 library preparation batch in order to reduce its potential bias. Fold-change values in miRNA abundance
136 between responders and non-responders were calculated as the ratio of normalized counts in
137 responders (*i.e.* patients exhibiting meaningful clinical improvement) to the normalized counts in the

138 non-responders (patients exhibiting lack of clinical improvement), and transformed to log base 2.
139 Statistical significance was determined using the Wald test.

140 Feature scaling to the range of [0-1] was further done for DESeq2 normalized counts of miR-133a and
141 miR-206 by applying min-max scaling, whereby the scaled value (x') is calculated by subtracting the
142 minimum value of each feature [$\min(x)$] from each individual observation (x), and further divided by
143 the difference between the maximum and the minimum value [$\max(x) - \min(x)$], as shown below

$$144 \quad x' = \frac{x - \min(x)}{\max(x) - \min(x)}$$

145
146 Scaled values were then summed to generate a devised feature termed miR-133a/206.

147 Correlation between miRNA levels and the clinical improvement in HFMSE score (HFMSE score post
148 treatment – HFMSE score pretreatment) was calculated by both linear regression, wherein the
149 improvement is a numerical value, and logistic regression, wherein the improvement is binarized into
150 “failure” (HFMSE score change ≤ 0 between post and pretreatment) and “success” (HFMSE score
151 change ≥ 3 between post and pretreatment). Logistic regression was performed with the aod and
152 ggplot2 packages in R³⁰, either for a single explanatory variable (either one miRNA gene or a feature
153 combined of two miRNAs) or as multinomial regression with multiple explanatory variables (a
154 combination of different miRNAs or miRNAs and clinical features). The fitted logistic regression
155 model is an exponential model from which predicted probabilities of “success” can be calculated based
156 on values of the explanatory variable(s). Exponential equations for all models are available in
157 supplementary table 1. Two values are derived from the logistic regression model: Chi-square
158 (χ^2), which expresses the goodness of fit for the whole model and Akaike's information criterion
159 (AIC)³¹, an estimation of the model prediction error. Statistical significance was determined for
160 Spearman rho and chi-square values, with p-values < 0.05 being considered statistically significant.

161 Leave-one-out-cross-validation was performed on the logistic regression model, whereby model
162 learning was done in n-1 samples out of the total n, and tested on the leave-one-out sample, yielding a
163 predicted success probability for each sample. This procedure was repeated n times. Receiver
164 operating characteristic (ROC) curves were generated by plotting true positive rates (sensitivity), i.e.
165 percentage of patients classified as responders, out of the total number of responders, against false
166 positive rates (100% - specificity), i.e. percentage of patients classified as responders, out of the total
167 number of non-responders, when each predicted success probability value is taken as a cut-off for
168 binary classification. Area under the curve (AUC) and its respective P-value were calculated for ROC

169 curves, given null hypothesis of $AUC = 0.5$. Graphs were generated with Prism 5 (GraphPad
170 Software, San Diego, California, USA).

171 **Results**

172 **Next-Generation Sequencing Analysis in the CSF of SMA Patients Treated with Nusinersen**

173 We sought to explore miRNAs expressed in the CSF as potential biomarkers for monitoring response
174 to nusinersen and to help determine, prior to treatment initiation, whether a patient was more or less
175 likely to respond to the therapy. We used next generation sequencing to investigate, without an *a priori*
176 bias, the comprehensive landscape of CSF miRNAs in 34 type II and type III SMA patients with
177 documented demographic and clinical information available (**Table 1**). We analyzed RNA-seq data
178 from CSF samples collected before treatment and analyzed these data in context of clinical response 6
179 months after initiation of nusinersen treatment. Data from additional 11 patients with HFMSE change
180 of a single or two units (1,2) were excluded.

181 After next generation sequencing, 2530 miRNA were annotated to the genome. Only 68 miRNA
182 species exceeded a cut-off of ≥ 100 unique molecular identifier (UMI) counts per sample, averaged on
183 all samples. 17 out of the 68 miRNAs changed post-treatment relative to pre-treatment (p -value < 0.05 ,
184 Wald test; **Figure S1**). Two miRNAs, miR-5694-5p and miR-3613-3p increased x 1.4-fold and miR-1-
185 5p decreased by 1.6-fold. These data suggest that only minor effects were observed on miRNA profile
186 after 6 months of nusinersen therapy.

187 **Baseline miR-206 / miR-103 Levels Predict Beneficial Response to Nusinersen Therapy**

188 The clinical response to nusinersen therapy is heterogeneous³². We tested whether the miRNA profile
189 at baseline would be different between patients that clinically responded to nusinersen therapy and
190 those that poorly responded. Responders (N=13) were defined as those demonstrating an increase of \geq
191 3 points²⁶ in the Hammersmith Functional Motor Scale Expanded (HFMSE) total score following six
192 months of nusinersen treatment, whereas non-responders (N=21) were defined as those with no
193 improvement or deterioration (≤ 0 points).

194 In responders' CSF, two miRNAs changed in a significant manner relative to non-responders: miR-
195 103b increased by 2.6-fold (Wald test: $p = 0.002$, **Figure 1**), and miR-206 decreased by 1.8-fold ($p =$
196 0.048). During these analyses, we noticed that similar to the downregulated miR-206 levels, other
197 miRNAs that are known to be expressed mainly in the skeletal muscle (*i.e.* myomiRs) were relatively

198 low in CSF of responders, including the miR-1-3p, miR-133a-3p and miR-133b, with 1.4-fold, 1.6-
199 fold, and 2.2-fold, respectively.

200 The levels of miR-206 were negatively correlated with clinical improvement, quantified as the change
201 in the HFMSE final score (Spearman rho = -0.43, 95% CI: -0.67 to -0.09, p = 0.01, **Figure 2A**). In
202 addition, an orthogonal logistic regression model supported that miR-206 levels correlated with
203 clinical response to nusinersen therapy ($\chi^2 = 7$, p = 0.008, Akaike's information criterion (AIC) = 42.2,
204 **Figure 2B**).

205 We next sought to validate the model on newly introduced data. We trained a machine learning
206 procedure on 33 samples and tested the prediction on the single sample that was left out. The 'leave
207 one out cross validation' (LOOCV) procedure, was reiterated 34 times. This analysis reveals that miR-
208 206 predicts response more than can be expected at random (area under the receiver operating
209 characteristic curve (ROC AUC) = 0.7, 95% CI: 0.51 – 0.88, p-value 0.06, **Figure S2**). None of the
210 other myomiRs (miR-1-3p, miR-133a-3p or miR-133b, **Figure S3**) displayed a significant correlation
211 with response to therapy. However, miR-103b levels correlated to the change in HFMSE score after
212 therapy (**Figure S4**). Taken together, these data suggest that myomiRs predict the response to
213 nusinersen therapy, and the miR-206 levels at baseline may predict the response to the nusinersen
214 therapy.

215 **Multi-Feature Classifiers of Response to Nusinersen Therapy**

216 We next considered simultaneously more than a single miRNA. The correlation of miR-206 and miR-
217 133a-3p to clinical improvement and classification, when both are considered explanatory variables
218 with weighted contributions to the model (multinomial logistic regression, equation available in
219 supplementary table 1), was higher than when miR-206 was considered as a single feature ($\chi^2 = 9$, p =
220 0.01, AIC = 42.1; ROC AUC 0.74, 95% CI: 0.55 – 0.92, p = 0.022, **Figure 3A**). None of the other
221 miRNAs (miR-1-3p, miR-103b or miR-133b) displayed an improved prediction capacity when added
222 on to miR-206 (**Figure S5A-C**). Thus, a feature composed of miR-206 and miR-133a-3p levels has an
223 improved prediction capacity for nusinersen therapy response. Adding SMA type (III vs II) improved
224 the correlation even further (<miR-206 + miR-133a-3p + SMA type>, $\chi^2 = 12$, p = 0.007, AIC =
225 41.35). We preserved the prediction capacity also by performing leave one out cross validation
226 (LOOCV) (AUC = 0.73, 95% CI: p = 0.024, **Figure 3B**). Input about patient sex further improved
227 prediction (<miR-206 + miR-133a-3p + SMA type+sex>, $\chi^2 = 14.5$, p = 0.006, AIC = 40.7; ROC AUC
228 = 0.76, 95 CI%: 0.56 – 0.95, p = 0.01, **Figure 3C**), with males being less likely to respond to therapy.

229 Patient age did not improve prediction ($\chi^2 = 14.9$, $p = 0.01$, AIC = 42.4; ROC AUC = 0.7, 95% CI:
230 0.475 – 0.925, $p > 0.05$).

231 In addition to the multinomial regression of miR-133a and miR-206, we also devised a feature by
232 normalization of the miRNA values by min-max scaling and summation of the scaled values. The new
233 predictor, miR-133a/206, displays a χ^2 of 9 ($p = 0.003$, **Figure 4A**), with a drop in predicted model
234 errors relative to when miR-133a-3p and miR-206 are independently considered (AIC 40.2 vs. 42.1,
235 respectively). The single standardized feature, miR-133a/206, displays ROC AUC of 0.74 (95% CI:
236 0.55 – 0.92, $p = 0.02$, **Figure 4B**) and information about SMA type (II or III based on clinical
237 manifestation) and sex further improved correlation to clinical response and predictive capacity ($\chi^2 =$
238 14.5, $p = 0.002$, AIC = 38.8; ROC AUC = 0.784, 95% CI: 0.6 – 0.97, $p = 0.006$, **Figure 4C**). In
239 summary, two miRNA in the CSF are able to predict response to nusinersen therapy in SMA type II
240 and III patients and may be useful for pre-treatment clinical decisions.

241 **Discussion**

242 Given the expanding treatment options available for motor neuron diseases, the discovery of novel
243 biomarkers to help track disease progression and therapeutic response is urgent. Here, we report novel
244 findings derived from the first screening for small RNAs in the CSF of type II/III SMA patients treated
245 with nusinersen. These data demonstrate that baseline levels of the myomiRs miR-133a-3p and miR-
246 206 are associated with the response to nusinersen therapy, suggesting that these myomiRs could play
247 an important role in the clinical setting to help identify those patients most likely to demonstrate a
248 more robust response to nusinersen therapy. In presenting these data, we hope to encourage
249 incorporation of examination of CSF levels of miR-133a-3p and miR-206 as well as other myomiRs in
250 longitudinal follow-up across cohorts of SMA patients receiving nusinersen or other novel therapies to
251 help validate the current findings.

252 Identifying biomarkers to track SMA progression and the response to molecular therapies is an
253 important focus of our group and others. We have previously demonstrated the usefulness of
254 electrophysiologic measures of peripheral denervation to track peripheral motor unit integrity^{33, 34}.
255 Circulating SMN protein levels is a candidate biomarker for monitoring SMA disease progression,
256 although changes in peripheral SMN levels are not expected with at least two of the three currently
257 FDA-approved therapies³⁵. CSF and plasma neurofilaments are markers of neuronal damage and have
258 been identified as a potential treatment responsive biomarker in SMA and other neurodegenerative
259 diseases, but baseline CSF or circulating neurofilament levels do not seem to necessarily predict
260 treatment response³⁶⁻³⁹. With 3 FDA-approved therapies and the anticipation of additional emerging
261 treatments for SMA, comprehensive longitudinal cohort studies remain critically necessary to identify
262 useful biomarkers that could predict the response to individual therapies.

263 One striking finding from our observations here is that myomiR levels were detected in the CSF and
264 that CSF levels decreased in SMA patients that responded to nusinersen, when compared to those who
265 presented a limited response. Although the myomiRs discussed here were identified via an unbiased
266 screening approach in CSF, our data corroborate recent findings demonstrating that serum myomiRs
267 levels are readouts of nusinersen response in SMA¹⁹; We propose a model, whereby the presence of
268 myomiRs in SMA CSF could be indicating blood-CSF barrier or blood-spinal cord disruption^{40,41},
269 enabling the entrance of miRNAs that are derived from breakdown of muscle cells in the setting of
270 acute denervation¹⁶⁻¹⁸. Thus, lower myomiR levels prior to treatment with nusinersen, which predicts

271 those with a better response, could reflect either reduced muscle cell breakdown and/or blood to CSF
272 barrier integrity or both.

273

274 We previously demonstrated that serum creatinine, a product of skeletal muscle creatine metabolism,
275 was also identified as a candidate biomarker to track SMA disease progression⁴², and that creatinine
276 maybe a sensitive predictor for the onset of denervation in infants with 3 *SMN2* copies⁴². Similarly,
277 circulating creatine kinase (CK) levels correlate with SMA severity and decreased during nusinersen
278 therapy⁴³. Therefore, in the future creatine capacity to predict response to Nusinersen therapy may be
279 tested by protein biomarkers, on their own, or in combination with miRNAs, such as miR-206/133a-
280 3p.

281 In summary, the current study demonstrates that the levels of muscle microRNAs miR-206 and miR-
282 133 in CSF can predict the clinical response to nusinersen treatment in SMA patients. These novel
283 findings have high clinical relevance and may prove useful in helping to design appropriate protocols
284 intended to refine and improve treatment outcomes.

285 **Disclosures**

286 CRRA and KJS are inventors on a patent filed by Mass General Brigham that describes genome-
287 engineering technologies to treat SMA. KJS has received clinical trial funding from AveXis/Novartis
288 and Biogen. She has received speaker fees from Biogen and has served on scientific advisory boards
289 for AveXis, Biogen, Roche/Genentech.

290 SA has received clinical trial funding from AveXis/Novartis Gene Therapies and Biogen and has
291 served on scientific advisory boards for AveXis/Novartis Gene Therapies.

292

293 **Acknowledgments**

294 EH is the Mondry Family Professorial Chair and Head of the Nella and Leon Benozziyo Center for
295 Neurological Diseases. Research at Hornstein lab is supported by CReATe consortium and ALSA
296 (program: ‘Prognostic value of miRNAs in biofluids from ALS patients’), RADALA Foundation;
297 AFM Telethon (20576); Weizmann - Brazil Center for Research on Neurodegeneration at Weizmann
298 Institute of Science; the Minerva Foundation with funding from the Federal German Ministry for
299 Education and Research, ISF Legacy Heritage Fund 828/17; Israel Science Foundation 135/16; 392/21;
300 393/21; 3497/21. Target ALS 118945; Thierry Latran Foundation for ALS Research. the European
301 Research Council under the European Union’s Seventh Framework Programme (FP7/2007–

302 2013)/ERC grant agreement number 617351; ERA-Net for Research Programmes on Rare Diseases
303 (eRARE FP7) via Israel Ministry of Health; Dr. Sydney Brenner and friends, Edward and Janie
304 Moravitz, A. Alfred Taubman through IsrALS, Yeda-Sela, Yeda-CEO, Israel Ministry of Trade and
305 Industry; Y. Leon Benozio Institute for Molecular Medicine, Kekst Family Institute for Medical
306 Genetics; David and Fela Shapell Family Center for Genetic Disorders Research; Crown Human
307 Genome Center; Nathan, Shirley, Philip and Charlene Vener New Scientist Fund; Julius and Ray
308 Charlestein Foundation; Fraida Foundation; Wolfson Family Charitable Trust; Adelis Foundation;
309 Merck (United Kingdom); M. Halphen; and Estates of F. Sherr, L. Asseof, L. Fulop. NSY was
310 supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science
311 Research Center. IM was supported by Teva Pharmaceutical Industries Ltd. as part of the Israeli
312 National Network of Excellence in Neuroscience (NNE, fellowship 117941).
313 CRRA was funded by MGH Executive Committee on Research. KJS was funded by NIH NICHD
314 R01HD054599, NIH NINDS R21NS108015, Biogen, AveXis and Cure SMA. We are grateful to all
315 the patients and families who participated in this study.

316 References

- 317 1. Ogino S, Leonard DG, Rennert H, Wilson RB. Spinal muscular atrophy genetic testing experience at an
318 academic medical center. *J Mol Diagn* 2002;4:53-58.
- 319 2. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked
320 spinal muscular atrophy - a literature review. *Orphanet J Rare Dis* 2017;12:124.
- 321 3. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. In: Adam MP, Ardinger HH, Pagon RA, et
322 al., eds. *GeneReviews*((R)). Seattle (WA)1993.
- 323 4. Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and
324 challenges. *Nat Rev Neurol* 2018;14:214-224.
- 325 5. Faravelli I, Nizzardo M, Comi GP, Corti S. Spinal muscular atrophy--recent therapeutic advances for an
326 old challenge. *Nat Rev Neurol* 2015;11:351-359.
- 327 6. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and
328 modification of the phenotype by SMN2. *Genet Med* 2002;4:20-26.
- 329 7. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2
330 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of
331 spinal muscular atrophy. *Am J Hum Genet* 2002;70:358-368.
- 332 8. Crawford TO, Paushkin SV, Kobayashi DT, et al. Evaluation of SMN protein, transcript, and copy
333 number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. *PLoS One*
334 2012;7:e33572.
- 335 9. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating
336 Oligonucleotides. *Nucleic Acid Therapeutics* 2017;27:67-69.
- 337 10. Messina S. New Directions for SMA Therapy. *Journal of Clinical Medicine* 2018;7:251.
- 338 11. Emde A, Eitan C, Liou LL, et al. Dysregulated miRNA biogenesis downstream of cellular stress and
339 ALS-causing mutations: a new mechanism for ALS. *EMBO J* 2015;34:2633-2651.
- 340 12. Reichenstein I, Eitan C, Diaz-Garcia S, et al. Human genetics and neuropathology suggest a link
341 between miR-218 and amyotrophic lateral sclerosis pathophysiology. *Science Translational Medicine*
342 2019;11:eaav5264.
- 343 13. Haramati S, Chapnik E, Sztainberg Y, et al. miRNA malfunction causes spinal motor neuron disease.
344 *Proc Natl Acad Sci U S A* 2010;107:13111-13116.
- 345 14. Chen J-F, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal
346 muscle proliferation and differentiation. *Nature genetics* 2006;38:228-233.
- 347 15. Chen J-F, Tao Y, Li J, et al. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell
348 proliferation and differentiation by repressing Pax7. *Journal of Cell Biology* 2010;190:867-879.
- 349 16. de Andrade HM, de Albuquerque M, Avansini SH, et al. MicroRNAs-424 and 206 are potential
350 prognostic markers in spinal onset amyotrophic lateral sclerosis. *J Neurol Sci* 2016;368:19-24.
- 351 17. Toivonen JM, Manzano R, Oliván S, Zaragoza P, Garcia-Redondo A, Osta R. MicroRNA-206: a
352 potential circulating biomarker candidate for amyotrophic lateral sclerosis. *PLoS One* 2014;9:e89065.
- 353 18. Waller R, Goodall EF, Milo M, et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential
354 biomarkers for amyotrophic lateral sclerosis (ALS). *Neurobiol Aging* 2017;55:123-131.
- 355 19. Bonanno S, Marcuzzo S, Malacarne C, et al. Circulating MyomiRs as Potential Biomarkers to Monitor
356 Response to Nusinersen in Pediatric SMA Patients. *Biomedicine* 2020;8:21.
- 357 20. Coenen-Stass AML, Magen I, Brooks T, et al. Evaluation of methodologies for microRNA biomarker
358 detection by next generation sequencing. *RNA Biol* 2018;15:1133-1145.
- 359 21. Magen I, Yacovzada N-S, Warren JD, et al. miRNA biomarkers for diagnosis of ALS and FTD,
360 developed by a nonlinear machine learning approach. *medRxiv* 2021:2020.2001.2022.20018408.
- 361 22. Magen I, Yacovzada NS, Yanowski E, et al. Circulating miR-181 is a prognostic biomarker for
362 amyotrophic lateral sclerosis. *bioRxiv* 2021:833079.
- 363 23. Glanzman AM, Mazzone ES, Young SD, et al. Evaluator Training and Reliability for SMA Global
364 Nusinersen Trials1. *J Neuromuscul Dis* 2018;5:159-166.
- 365 24. O'Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith
366 Functional Motor Scale for SMA II and III patients. *Neuromuscul Disord* 2007;17:693-697.

- 367 25. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal
368 Muscular Atrophy. *N Engl J Med* 2018;378:625-635.
- 369 26. Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular
370 atrophy. *PLoS One* 2009;4:e5268.
- 371 27. Kohen R, Barlev J, Hornung G, et al. UTAP: User-friendly Transcriptome Analysis Pipeline. *BMC*
372 *bioinformatics* 2019;24:154.
- 373 28. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep
374 sequencing data. *Nucleic Acids Res* 2014;42:D68-73.
- 375 29. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data
376 with DESeq2. *Genome Biol* 2014;15:550.
- 377 30. Multiple Logistic Regression. *Applied Logistic Regression* 2000: 31-46.
- 378 31. Akaike H. Information Theory and an Extension of the Maximum Likelihood Principle. In: Parzen E,
379 Tanabe K, Kitagawa G, eds. *Selected Papers of Hirotugu Akaike*. New York, NY: Springer New York,
380 1998: 199-213.
- 381 32. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal
382 Muscular Atrophy. *N Engl J Med* 2017;377:1723-1732.
- 383 33. Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular
384 atrophy. *Muscle Nerve* 2002;25:445-447.
- 385 34. Lewelt A, Krosschell KJ, Scott C, et al. Compound muscle action potential and motor function in
386 children with spinal muscular atrophy. *Muscle Nerve* 2010;42:703-708.
- 387 35. Alves CRR, Zhang R, Johnstone AJ, et al. Whole blood survival motor neuron protein levels correlate
388 with severity of denervation in spinal muscular atrophy. *Muscle Nerve* 2020;62:351-357.
- 389 36. Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a potential biomarker for spinal muscular
390 atrophy. *Ann Clin Transl Neurol* 2019;6:932-944.
- 391 37. Eichelberger EJ, Alves CRR, Zhang R, et al. Increased systemic HSP70B levels in spinal muscular
392 atrophy infants. *Ann Clin Transl Neurol* 2021.
- 393 38. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic
394 stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.
395 *Neuromuscul Disord* 2019;29:842-856.
- 396 39. Winter B, Guenther R, Ludolph AC, Hermann A, Otto M, Wurster CD. Neurofilaments and tau in CSF
397 in an infant with SMA type 1 treated with nusinersen. *J Neurol Neurosurg Psychiatry* 2019;90:1068-
398 1069.
- 399 40. Müschen LH, Osmanovic A, Binz C, et al. Cerebrospinal Fluid Parameters in Antisense
400 Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients. *Brain Sciences* 2021;11:296.
- 401 41. Somers E, Lees RD, Hoban K, et al. Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular
402 Atrophy. *Annals of neurology* 2016;79:217-230.
- 403 42. Alves CRR, Zhang R, Johnstone AJ, et al. Serum creatinine is a biomarker of progressive denervation in
404 spinal muscular atrophy. *Neurology* 2020;94:e921-e931.
- 405 43. Freigang M, Wurster CD, Hagenacker T, et al. Serum creatine kinase and creatinine in adult spinal
406 muscular atrophy under nusinersen treatment. *Ann Clin Transl Neurol* 2021.

407

Figure legend

408 **Figure 1. Pre-treatment miRNA signature associates with the response to nusinersen treatment.**

409 MA plot of differential miRNA expression in responders (N=13, patients with HFMSE change ≥ 3 after
410 6 months of treatment) versus non-responders (N=21, HFMSE change ≤ 0). Data from additional 11
411 patients with HFMSE change of a single or two units (1,2) were excluded. Log 2 transformed fold
412 change (y-axis), against mean miRNA abundance (x-axis). Red: significantly changed miRNAs
413 ($p < 0.05$, Wald test). Higher miR-103b levels and lower muscle enriched miRNA miR-1-3p, miR-
414 133a/b and miR-206 levels are observed in prospective nusinersen responders.

415

416 **Figure 2. miR-206 levels are associated with clinical improvement of SMA patients following 6-**

417 **month nusinersen treatment. (A)** Negative correlation of miR-206 levels with response to nusinersen
418 therapy (as post-treatment – pre-treatment HFMSE score difference, Spearman rho = -0.43, $p = 0.01$)
419 number of patients. **(B)** Logistic regression of baseline miR-206 levels on clinical dichotomized
420 response to therapy: responders (N=13, HFMSE change ≥ 3 after 6 months of treatment) versus non-
421 responders (N=21, HFMSE change ≤ 0). Statistical significance of the logistic regression model
422 goodness of fit was assessed by the chi-square test. AIC, Akaike's information criterion.

423 **Figure 3. A predictor, based on miR-133a and miR-206 predicts response to nusinersen. ROC**

424 curves **(A)** miR-133a-3p + miR-206 **(B)** miR-133a-3p + miR-206 + SMA type **(C)** miR-133a-3p +
425 miR-206 + SMA type + sex with leave one out cross validation. **(D)** A summary of logistic regression
426 parameters for three multiple feature models.

427 **Figure 4. A predictor, based on a summation of the scaled values of miR-133a and miR-206**

428 **predicts response to nusinersen. (A)** Logistic regression analysis of miR-133a/206 at baseline and
429 clinical response to therapy after 6 months of nusinersen treatment. ROC curves based on LOOCV for
430 **(B)** miR-133a/206 and **(C)** miR-133a/206 with SMA type and sex. **(D)** A summary of logistic
431 regression parameters for two models.

432 **Supplementary Figure 1. CSF miRNA signature after nusinersen treatment vs pre-treatment in**
433 **the same patients.** MA plot showing, in the X-axis, miRNA levels averaged across CSF samples
434 collected from 34 patients at both baseline (pre-treatment) and after 6 months of nusinersen treatment
435 (68 samples in total). Y-axis, miRNA levels after treatment versus pre-treatment (log 2 of fold
436 difference). Each dot represents a single miRNA gene. Dots above/below the horizontal dashed line are
437 miRNAs with higher/lower levels post-treatment. Red dots represent miRNAs with p-value <0.05
438 (unadjusted).

439

440 **Supplementary Figure 2.** Receiver operating characteristic (ROC) curve based on miR-206 logistic
441 regression and leave-one-out cross validation (LOOCV). True positive rate (sensitivity, y-axis) against
442 false positive rate (100%-specificity, x-axis). Values of predicted success probability in each patient, as
443 a cut-off for binary classification.

444

445 **Supplementary Figure 3. Association of myomiRs with clinical improvement of SMA patients**
446 **during nusinersen treatment. Spearman correlation** of baseline miR-1-3p (A), miR-133a-3p (B)
447 and miR-133b (C) with the difference in HFMSE score following nusinersen. **Logistic regression**
448 analysis of baseline miR-1-3p (D), miR-133a-3p (E) and miR-133b (F) levels on clinical response,
449 after 6 months of nusinersen treatment. **ROC curves** based on LOOCV for miR-1-3p (G), miR-133a-
450 3p (H) and miR-133b (I).

451

452 **Supplementary Figure 4. Increased miR-103b in the CSF modestly predicts clinical**
453 **improvement of SMA patients during nusinersen treatment.** (A) miR-103b levels at baseline
454 exhibit a positive and significant correlation (Spearman rho = 0.39, p=0.02) with the difference in
455 HFMSE score following nusinersen. (B) Logistic regression analysis of miR-103b levels at baseline
456 and clinical response to therapy after 6 months of nusinersen treatment. (C) ROC curve based on
457 LOOCV for the logistic regression model.

458

459 **Supplementary figure 5.** ROC curves for models of (A) miR-206 + miR-103b (B) miR-206 + miR-
460 133b and (C) miR-206 + miR-1-3p.

Cohort origin	Before exclusion			After exclusion		
	N (% females)	Type (II/III)	Median age at treatment initiation in years (range)	N (% females)	Type (II/III)	Median age at treatment initiation in years (range)
Schneider Medical Center	13 (69%)	7/6	11.0 (2.3 – 19.0)	7 (100%)	4/3	6.4 (2.9 – 17.3)
Tel Aviv Medical Center	20 (55%)	9/11	11.7 (1.7 - 24.4)	17 (59%)	8/9	11.1 (1.7 - 24.4)
Massachusetts General Hospital	12 (42%)	5/7	7.5 (2.1 - 56.6)	10 (40%)	4/6	11.1 (2.1 - 56.6)
Total	45 (55%)	21/24	11.0 (1.7 - 56.6)	34 (53%)	16/18	11.0 (1.7 - 56.6)

Table 1. Gender, age, SMA type and SMN2 copy number distribution for each cohort. 11 patients (6 from Schneider, 3 from Tel Aviv and 2 from MGH) whose change in HFMSE score between after 6 months of treatment was 1 or 2 were excluded from analysis.

Figure 1






Figure 3


A



B






C



D

Model	χ^2	χ^2 p-value	AIC
miR-133a + miR-206	9	0.01	42.1
miR-133a + miR-206 + SMA type	12	0.007	41.3
miR-133a + miR-206 + SMA type + sex	14.5	0.006	40.7

Figure 4



D

Model	χ^2	χ^2 p-value	AIC
miR-133a/206	9	0.003	40.2
miR-133a/206 + SMA type + sex	14.5	0.002	38.8